![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 30-Jul-2012[ | E-mail |
Share ] Contact: Gwen van der Heide
g.heide@elsevier.com
31-020-485-2594
Elsevier
Amsterdam, July 30, 2012 Elsevier, a world-leading provider of scientific, technical and medical information products and services, announces the launch of Applied and Translational Genomics, an open access journal. The journal is dedicated to publishing articles on applied genomics and translational research.
The completion of the human genome project gave way to research that takes the genetic code and applies it to research that aims to eradicate disease. This applied genomic research is most relevant in the area of translational research, or, the field of research which finds itself between that of basic research and clinical trials. Applied and Translational Genomics serves as a home for this exponentially expanding field of research.
"Like any other scientific and technological field, an important outcome measure of research is its meeting societal expectations in wide ranging domains including economic gains, improving living standards, compatible with socio-cultural and religious practices, keeping consistent with contemporary ethical, moral and legal requirements," said Dhavendra Kumar, MD, Editor-in-Chief of the journal. "There are several potential areas where rapid advances in scientific understanding and avenues for translational research seriously need to be considered. Applied and Translational Genomics aims to be the premier journal to publish this cutting-edge research."
Bart Wacek, Executive Publisher Life Sciences at Elsevier added, "We are delighted that we have been able to launch this journal in this important area of scientific research. Applied and Translational Genomics has a broad scope and provides a home for high quality research in the areas that sometimes get caught in between basic research and clinical trials."
###
For more information or to submit and article, go to: Applied and Translational Genomics. First articles to be published in the journal are now available through ScienceDirect.
About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media contact
Gwen van der Heide
Elsevier
+ 31 20 485 2594
g.heide@elsevier.com
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 30-Jul-2012[ | E-mail |
Share ] Contact: Gwen van der Heide
g.heide@elsevier.com
31-020-485-2594
Elsevier
Amsterdam, July 30, 2012 Elsevier, a world-leading provider of scientific, technical and medical information products and services, announces the launch of Applied and Translational Genomics, an open access journal. The journal is dedicated to publishing articles on applied genomics and translational research.
The completion of the human genome project gave way to research that takes the genetic code and applies it to research that aims to eradicate disease. This applied genomic research is most relevant in the area of translational research, or, the field of research which finds itself between that of basic research and clinical trials. Applied and Translational Genomics serves as a home for this exponentially expanding field of research.
"Like any other scientific and technological field, an important outcome measure of research is its meeting societal expectations in wide ranging domains including economic gains, improving living standards, compatible with socio-cultural and religious practices, keeping consistent with contemporary ethical, moral and legal requirements," said Dhavendra Kumar, MD, Editor-in-Chief of the journal. "There are several potential areas where rapid advances in scientific understanding and avenues for translational research seriously need to be considered. Applied and Translational Genomics aims to be the premier journal to publish this cutting-edge research."
Bart Wacek, Executive Publisher Life Sciences at Elsevier added, "We are delighted that we have been able to launch this journal in this important area of scientific research. Applied and Translational Genomics has a broad scope and provides a home for high quality research in the areas that sometimes get caught in between basic research and clinical trials."
###
For more information or to submit and article, go to: Applied and Translational Genomics. First articles to be published in the journal are now available through ScienceDirect.
About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Nursing Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media contact
Gwen van der Heide
Elsevier
+ 31 20 485 2594
g.heide@elsevier.com
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2012-07/e-eln073012.php
blackout blackout congress censored jerry yang stop sopa justified
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.